Merck’s Merger with Schering-Plough Takes Everyone by Surprise

Many people were caught off-guard by Merck’s announcement that it would merge with Schering-Plough in a $41.1 billion dollar deal. According to this post on PharmExec.com this deal will take form of a “reverse merger,” which means that technically speaking Schering-Plough will inherit Merck even though they will operate under the Merck name.

Many believe that this reverse merger occurred because an existing international marketing agreement between Johnson & Johnson and Schering which allows Johnson to take all rights to sell Remicade and golimumab if Schering-Plough is acquired by another company. Still unknown is what part Johnson & Johnson will play in this huge merger. This will be something to we will look out for in the upcoming months.

Share this article with your social network, just click below to share now!

Share |